NCI - National Cancer Institute
Juvenile myelomonocytic leukemia (JMML) is a rare and high-mortality hematologic malignancy affecting young children. Currently, the primary treatment for JMML is allogeneic hematopoietic stem cell transplantation (HSCT); however, relapse remains a significant risk following transplant. In the Concept phase of our research, Gencyte established the synNotch-controlled PMA CAR platform and generated preliminary in vitro proof-of-concept data for JMML treatment. In Phase I, the company will conduct in vivo assays using immunocompromised mice to evaluate synNotch-controlled PMA CAR-T cells. The company also plans to optimize leads to reduce HAMA (human anti-mouse antibody) responses, improving safety for human application. Then in vitro and in vivo functional assays will be conducted on the optimized leads. Preclinical development will follow, focusing on producing GLP/GMP-grade materials and completing IND-enabling studies to support an IND application.
Up to $500K
2026-09-11
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
One-time $749 fee · Includes AI drafting + templates + PDF export
Dynamic Cognitive Phenotypes for Prediction of Mental Health Outcomes in Serious Mental Illness
NIMH - National Institute of Mental Health — up to $18.3M
COORDINATED FACILITIES REQUIREMENTS FOR FY25 - FACILITIES TO I
NCI - National Cancer Institute — up to $15.1M
Leveraging Artificial Intelligence to Predict Mental Health Risk among Youth Presenting to Rural Primary Care Clinics
NIMH - National Institute of Mental Health — up to $15.0M
Feasibility of Genomic Newborn Screening Through Public Health Laboratories
OD - NIH Office of the Director — up to $14.4M
WOMEN'S HEALTH INITIATIVE (WHI) CLINICAL COORDINATING CENTER - TASK AREA A AND A2
NHLBI - National Heart Lung and Blood Institute — up to $10.2M
Metal Exposures, Omics, and AD/ADRD risk in Diverse US Adults
NIA - National Institute on Aging — up to $10.2M